Biovail Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products used in the treatment of specialty central nervous system disorders. Its product portfolio includes Wellbutrin XL for the treatment of depression in adults; Xenazine for the treatment of chorea associated with Huntington's disease; Aplenzin for the treatment of major depressive disorder; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; Ultram ER for the management of chronic pain in adults; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Glumetza for the control of hyperglycemia in adult patients with type 2 diabetes; Ralivia for the management of pain of moderate severity; Nitoman for the treatment of hyperkinetic movement disorders; Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; and Zyban for smoking cessation treatment. In addition, it distributes various other pharmaceutical products, including Ativan for the management of anxiety disorders; Vasotec and Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company?s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company distributes its products primarily through third party commercialization relationships in the United States and Canada. Biovail Corporation was founded in 1983 and is headquartered in Mississauga, Canada.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion Technology, Impede Technology, and other technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, decongestants, and various other opioid analgesics. The company?s lead product candidate, Acurox Tablet, is an orally administered immediate release tablet containing oxycodone HCl as its active analgesic ingredient. Its opioid analgesic product candidates are used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. The company is also investigating and developing mechanisms to incorporate abuse deterrent characteristics into abused and misused pharmaceutical products through laboratory testing of a product candidate developed with its Impede Technology, which is intended to inhibit the conversion of pseudoephedrine HCl into methamphetamine. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize various opioid analgesic products utilizing the company?s proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.